Figure 1.

Vaccine efficacy to influenza immunization in multiple sclerosis (MS) patients on dimethyl fumarate (DMF) and healthy controls. (A) Pre- and post-vaccine seroprotection rates, defined by a strain-specific anti-influenza titer of ≥1:40. (B) Vaccine responder rates among the two cohorts. Vaccine response was defined by seroconversion and/or significant (≥4-fold) specific titer increases in ≥2/4 influenza strains. (C) Increases in strain-specific antibody titers among the two cohorts at 34.1 days ( ± 9.4) post-vaccination compared with baseline. Dotted lines indicate the cut-off titer for seroprotection.